9 unknown, 1 terminated. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 7, Terminated 1 |
| Phase 1 | 5 | Unknown 4, Terminated 1 |
Follow TQ-B3525: new trials by email Literature Review of TQ-B3525 trials Research Report on TQ-B3525
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Material Balance Study of TQ-B3525 TQ-B3525 - Chronic Kidney Diseases, Magnetic Resonance Imaging | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 8 | 2023-01-01 | 2023-01-12 |
| A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma TQ-B3525 tablets - Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 23 | 2021-06-05 | 2023-11-29 |
| A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors TQ-B3525 tablet - Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 90 | 2021-04-23 | 2021-06-01 |
| A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma (DLBCL) TQ-B3525 tablets - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 93 | 2021-01-20 | 2021-08-18 |
| A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma(PTCL) TQ-B3525 - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 78 | 2020-12-01 | 2020-11-04 |
| TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss TQB3525 - Safety Issues, Efficacy, Self | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 29 | 2020-10-01 | 2020-12-31 |
| A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL) TQ-B3525 - Relapsed / Refractory Mantle Cell Lymphoma (MCL) | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 102 | 2020-07-20 | 2020-09-11 |
| A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer TQ-B3525, Fulvestrant injection - HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 42 | 2020-07-01 | 2020-04-21 |
| A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) TQ-B3525 - Relapsed / Refractory Follicular Lymphoma | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 80 | 2020-05-20 | 2020-07-01 |
| A Study of TQ-B3525 on Tolerance and Pharmacokinetics TQ-B3525 - Relapsed or Refractory Lymphoma or Advanced Cancer | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2018-06-20 | 2023-04-14 |
Recurrence (2) · Chondrosarcoma (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Osteosarcoma (1) · Ovarian Neoplasms (1) · Renal Insufficiency, Chronic (1) · Sarcoma, Ewing (1) · Uterine Cervical Neoplasms (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (9) · Peking University People's Hospital (1)
China (10)
Huaqing Wang, doctor (1) · Wei Guo, Ph.D and M.D. (1) · Wenqi Jiang, doctor (1)